MingDe Lin, PhD
Assistant Professor Adjunct, Radiology & Biomedical Imaging
Research & Publications
Biography
News
Research Summary
Dr. Lin's primary focus is in overseeing, coordinating, driving and directing research collaborations between Visage Imaging and high profile academic hospitals in North America in areas that include Artificial Intelligence (AI) and Machine Learning (ML) in the Radiology enterprise diagnostic imaging solutions space. Furthermore, Dr. Lin, as principle investigator on NIH funded work, also develops technologies to better characterize, diagnose, and treat liver lesions.
Extensive Research Description
Dr. Lin is the inventor of 3D quantification TACE therapy response tool (qEASL) and in collaboration with clinical partners, co-created, validated, and showed clinical relevance (ability to predict patient survival) that led to full transfer to commercial product.
Coauthors
Research Image
3D quantitative analysis (quantitative European Association for the Study of the Liver [qEASL]) of therapy response after intra-arterial therapy
Selected Publications
- Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH, Maltenfort MG, Pawlik T, Geschwind JF. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology 2016, 278: 275-84. PMID: 26131913, PMCID: PMC4695977, DOI: 10.1148/radiol.2015142951.
- Cancer: see, reach, treat.Geschwind JJ, Lin M. Cancer: see, reach, treat. International Innovation : Disseminating Science, Research And Technology 2015, 174: 13-15. PMID: 26617978, PMCID: PMC4659508.
- Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI.Chapiro J, Lin M, Duran R, Schernthaner RE, Geschwind JF. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Review Of Anticancer Therapy 2015, 15: 199-205. PMID: 25371052, PMCID: PMC4304995, DOI: 10.1586/14737140.2015.978861.
- Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?Loffroy R, Lin M, Yenokyan G, Rao PP, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Liapi E, Geschwind JF. Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma? Radiology 2013, 266: 636-48. PMID: 23143027, PMCID: PMC3558876, DOI: 10.1148/radiol.12112316.